Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
for Proteinuric Kidney Disease
167 locations incl. Alabaster
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All·Age: 10 - 65
Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022